VITAMIN D AND PROSTATE CANCER

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 该建议的中心假设是，每日剂量的维生素D3（4，000 IU）将导致大量诊断为早期，低级别，低风险前列腺癌的患者血清PSA水平可测量的降低。 将评价每日补充4，000 IU维生素D3持续12个月在维生素D缺乏症受试者中恢复循环25（OH）D3水平的安全性和有效性。 此外，还将评估每天补充4，000 IU维生素D3持续12个月是否会导致血清PSA水平可测量和显著降低。 这项研究的完成将为更大规模的前瞻性研究铺平道路，这些研究旨在证明，鉴于相当一部分前列腺癌的进展非常缓慢，适当的维生素D治疗方案将为观察等待提供一种极好的替代或辅助方法。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The central hypothesis of this proposal is that a daily dose of vitamin D3 (4,000 IU) will result in a measurable decrease of serum PSA levels in a significant number of patients diagnosed with early stage, low-grade, low-risk prostate cancer. The safety and efficacy of a daily vitamin D3 supplement of 4,000 IU taken for twelve months in restoring circulating 25(OH)D3 levels in subjects with hypovitaminosis D will be evaluated. In addition, it will be evaluated whether a daily supplement of 4,000 IU of vitamin D3 taken for twelve months will result in a measurable and significant decrease in serum PSA levels. Completion of this study will pave the way for larger prospective studies aimed at demonstrating that, given the very slow progression of a significant proportion of prostate cancers, appropriate regimens of vitamin D would provide an excellent alternative or adjunct to watchful waiting .